Denali Therapeutics Inc.
NEWS
It’s no secret that drugmakers have struggled to develop a therapeutic to treat or halt the onset of Alzheimer’s disease. Multiple drugs have failed in late-stage trials and some companies, such as Pfizer, have largely given up on the space.
Denali Therapeutics, located in South San Francisco, California, had a lot of news to share today.
A look at whether big money and big deals will be in store for 2018.
Will this new buy be enough for Celgene investors?
Takeda CEO Christophe Weber is sticking to his game plan of actively hunting deals that will expand its global presence and create a stronger international profile.
Although it was an average year for mergers and acquisitions in the biopharma industry, it was a stronger year for IPOs.
A look at what three ex-Genentech employees have accomplished at Denali so far.
With the raise, the company’s market valuation is currently $1.7B.
Denali plans to make a $100M IPO under the symbol DNLI.
JOBS
IN THE PRESS